Barchas Isaac sold IMNM

June 30, 2026 · Form 4 insider transaction

Barchas Isaac sold 101,050 shares of Immunome, Inc. at $21.12 per share, a transaction worth $2.13M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
101,050
Price
$21.12
Total value
$2.13M
RoleDirector
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJune 30, 2026
Filing dateJuly 2, 2026
Shares owned after308,504
OwnershipIndirect
10b5-1 planYes
AmendedNo

Footnotes

The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.; The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.; The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.; The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.; The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

View the original Form 4 on SEC EDGAR